Prospects for Therapies in Osteoarthritis
- PMID: 32055890
- PMCID: PMC8403110
- DOI: 10.1007/s00223-020-00672-9
Prospects for Therapies in Osteoarthritis
Abstract
Osteoarthritis (OA) is a chronic, debilitating disease affecting millions of people worldwide. Management of OA involves pharmacological and non-pharmacological approaches. Conventional pharmacological treatments have limited efficacy and are associated with a number of side-effects, restricting the number of patients who can use them. New pharmacological therapies for managing OA are required and a number have been developed targeting different tissues in OA: bone and cartilage, synovium and nerves. However, there has been overall limited success. Disease-modifying osteoarthritis drugs (DMOADs) are a putative class of therapies aimed at improving OA structural pathologies and consequent symptoms. Recent DMOAD studies have demonstrated some promising therapies but also provided new considerations for future trials.
Keywords: Cartilage; DMOAD; Inflammation; Nociceptive pain; Osteoarthritis; Synovitis.
© 2020. The Author(s).
Conflict of interest statement
AG reports no conflicts. PGC reports speakers’ bureaus or consultancies for Abbvie, Astra Zeneca, BMS, Centrexion, EMD Serono, Flexion Therapeutics, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Samumed and Stryker.
Similar articles
-
Update on novel pharmacological therapies for osteoarthritis.Ther Adv Musculoskelet Dis. 2019 Jul 23;11:1759720X19864492. doi: 10.1177/1759720X19864492. eCollection 2019. Ther Adv Musculoskelet Dis. 2019. PMID: 31384314 Free PMC article. Review.
-
Current Models for Development of Disease-Modifying Osteoarthritis Drugs.Tissue Eng Part C Methods. 2021 Feb;27(2):124-138. doi: 10.1089/ten.TEC.2020.0309. Epub 2021 Feb 4. Tissue Eng Part C Methods. 2021. PMID: 33403944 Free PMC article. Review.
-
New and emerging treatments for osteoarthritis management: will the dream come true with personalized medicine?Expert Opin Pharmacother. 2013 Oct;14(15):2059-77. doi: 10.1517/14656566.2013.825606. Expert Opin Pharmacother. 2013. PMID: 24044485 Review.
-
New developments in osteoarthritis pharmacological therapies.Rheumatology (Oxford). 2021 Dec 24;60(Suppl 6):vi1-vi11. doi: 10.1093/rheumatology/keab679. Rheumatology (Oxford). 2021. PMID: 34951922 Free PMC article. Review.
-
A brief review of current treatment options for osteoarthritis including disease-modifying osteoarthritis drugs (DMOADs) and novel therapeutics.Ann Med Surg (Lond). 2024 Jun 4;86(7):4042-4048. doi: 10.1097/MS9.0000000000002214. eCollection 2024 Jul. Ann Med Surg (Lond). 2024. PMID: 38989236 Free PMC article. Review.
Cited by
-
The effect of vitamin K insufficiency on histological and structural properties of knee joints in aging mice.Osteoarthr Cartil Open. 2020 Jun 2;2(3):100078. doi: 10.1016/j.ocarto.2020.100078. eCollection 2020 Sep. Osteoarthr Cartil Open. 2020. PMID: 36474686 Free PMC article.
-
Association of cardiovascular health with morbidity and mortality among U.S. adults with osteoarthritis: a population-based study.BMC Public Health. 2025 Apr 30;25(1):1587. doi: 10.1186/s12889-025-22530-9. BMC Public Health. 2025. PMID: 40307769 Free PMC article.
-
The Dysregulated Galectin Network Activates NF-κB to Induce Disease Markers and Matrix Degeneration in 3D Pellet Cultures of Osteoarthritic Chondrocytes.Calcif Tissue Int. 2021 Mar;108(3):377-390. doi: 10.1007/s00223-020-00774-4. Epub 2020 Nov 13. Calcif Tissue Int. 2021. PMID: 33185768 Free PMC article.
-
The Role of AIM2 Inflammasome in Knee Osteoarthritis.J Inflamm Res. 2022 Nov 28;15:6453-6461. doi: 10.2147/JIR.S392652. eCollection 2022. J Inflamm Res. 2022. PMID: 36467990 Free PMC article. Review.
-
Unveiling the Potential of Probiotics in Osteoarthritis Management.Curr Rheumatol Rep. 2024 Nov 23;27(1):2. doi: 10.1007/s11926-024-01166-5. Curr Rheumatol Rep. 2024. PMID: 39579259 Review.
References
-
- C Global Burden of Disease Study Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England) 2015;386(9995):743–800. doi: 10.1016/S0140-6736(15)60692-4. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical